Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
The randomized, double-blind, placebo-controlled phase 3 MATINEE study evaluated the safety and efficacy of mepolizumab in patients with COPD and type 2 inflammation.
MedPage Today on MSN3d
FDA OKs New Option for Rare Immune-Mediated VasculitisEGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Zacks.com on MSN22h
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ DrugsThis week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Adding GSK’s mepolizumab to standard inhaled treatment for COPD reduces the frequency of exacerbations in patients with type ...
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback